Successful treatment with daratumumab for splenectomy refractory immune‐mediated thrombotic thrombocytopenic purpura
- 20 October 2024
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 205 (6) , 2515-2518
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2024
- Daratumumab for refractory immune‐mediated thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2023
- Combination regimens containing daratumumab for initial diagnosed acquired thrombotic thrombocytopenic purpuraJournal of Thrombosis and Thrombolysis, 2023
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic PurpuraNew England Journal of Medicine, 2019
- Ofatumumab for TTP in a Patient with Anaphylaxis Associated with RituximabNew England Journal of Medicine, 2018
- Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpuraBlood, 2016
- Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2016
- Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpuraEuropean Journal of Haematology, 2007
- An evaluation of ciclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2006
- Splenectomy for the treatment of thrombotic thrombocytopenic purpuraBritish Journal of Haematology, 2005